Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 892,328
  • Shares Outstanding, K 53,337
  • Annual Sales, $ 193,120 K
  • Annual Income, $ 25,210 K
  • 60-Month Beta 0.35
  • Price/Sales 4.69
  • Price/Cash Flow 31.63
  • Price/Book 2.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.12
  • Number of Estimates 2
  • High Estimate 0.20
  • Low Estimate 0.04
  • Prior Year 0.19
  • Growth Rate Est. (year over year) -36.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.94 +12.02%
on 11/14/19
17.85 -6.27%
on 12/09/19
+1.75 (+11.68%)
since 11/13/19
3-Month
12.32 +35.83%
on 10/10/19
17.85 -6.27%
on 12/09/19
+3.14 (+23.11%)
since 09/13/19
52-Week
11.83 +41.42%
on 07/25/19
31.30 -46.55%
on 01/18/19
-9.42 (-36.02%)
since 12/13/18

Most Recent Stories

More News
Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will present its inaugural Trailblazer...

VNDA : 16.73 (-1.47%)
Vanda Pharmaceut Rises 1.06% on Heavy Volume: Watch For Potential Pullback

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $17.52 to a high of $17.84. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

VNDA : 16.73 (-1.47%)
Shares of VNDA Up 5.8% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Vanda Pharmaceut (NASDAQ:VNDA) on August 1st, 2019 at $15.82. In approximately 4 months, Vanda Pharmaceut has returned 5.79% as of today's recent price of $16.73.

VNDA : 16.73 (-1.47%)
SmarTrend Watching for Potential Pullback in Shares of Vanda Pharmaceut After 2.74% Gain

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $15.73 to a high of $16.10. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high...

VNDA : 16.73 (-1.47%)
Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019:

VNDA : 16.73 (-1.47%)
Top Ranked Value Stocks to Buy for November 14th

Top Ranked Value Stocks to Buy for November 14th

VNDA : 16.73 (-1.47%)
TNP : 3.86 (+2.93%)
QRTEA : 8.17 (-5.22%)
Coherus Bioscien has the Best Relative Performance in the Biotechnology Industry (CHRS , VNDA , ATRA , EPZM , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ATRA : 15.45 (-3.38%)
CHRS : 18.52 (+1.48%)
VNDA : 16.73 (-1.47%)
Vanda: 3Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported third-quarter net income of $100.4 million.

VNDA : 16.73 (-1.47%)
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019.

VNDA : 16.73 (-1.47%)
Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday, November 6, 2019, after the market...

VNDA : 16.73 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade VNDA with:

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 17.26
1st Resistance Point 17.00
Last Price 16.73
1st Support Level 16.58
2nd Support Level 16.42

See More

52-Week High 31.30
Fibonacci 61.8% 23.86
Fibonacci 50% 21.56
Fibonacci 38.2% 19.27
Last Price 16.73
52-Week Low 11.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar